SCHEMBL17968917

SCHEMBL17968917

CCCCCCCOc1ccc(-c2cnc(-c3ccc(CC(NC(=O)c4ccc(C(C)(C)C)s4)C(=O)NC(CC(=O)OCc4ccccc4)C(=O)O)cc3)nc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ITGB1 P05556 2/20 0.43
▸ ITGA4 P13612 2/20 0.43
▸ ITGB3 P05106 12/20 0.43
▸ ITGA2B P08514 12/20 0.43
▸ KLKB1 P03952 4/20 0.41
▸ PLG P00747 1/20 0.39
▸ MME P08473 1/20 0.39
▸ ACE P12821 1/20 0.39
▸ CPA1 P15085 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ ITGAV P06756 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16306042 1.00 ITGB1 (0.43) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL22384069 0.94 KLKB1 (0.41) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL19485472 0.94 KLKB1 (0.41) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL16305708 0.93 ITGB1 (0.50) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL22384144 0.93 ITGB1 (0.50) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL16305712 0.93 ITGB1 (0.50) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL16306073 0.93 ITGB1 (0.50) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL16305934 0.93 ITGB1 (0.50) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL22449242 0.91 SUCNR1 (0.44) ITGB1ITGA4ITGB3ITGA2BKLKB1
SCHEMBL15037134 0.91 SUCNR1 (0.44) ITGB1ITGA4ITGB3ITGA2BKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB1 3589/4885ITGA4 4651/4885ITGB3 4025/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB1 3589/4885ITGA4 4651/4885ITGB3 4025/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR ITGB1 3369/4885ITGA4 4604/4885ITGB3 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback